0.72 0.02 (2.86%)

New 52W Low in past week

2.0M XNAS Volume

High volume today

XNAS 04 Apr, 2025 5:30 PM (EDT)



Insider Trading disclosures for CERo Therapeutics Holdings Inc.

The latest disclosure was made by Lindsey Rolfe in CERo Therapeutics Holdings Inc. where a trade of 17,923 Stock Option (Right to Buy) done was reported to US exchanges on March 4, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Lindsey Rolfe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 17,923 17,923 - - Stock Option (Right to Buy)
Michael Byrnes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 17,923 17,923 - - Stock Option (Right to Buy)
Shami J. Patel Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 14,936 14,936 - - Stock Option (Right to Buy)
Kathleen D. Laporte Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 17,923 17,923 - - Stock Option (Right to Buy)
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Mar 2025 14,936 14,936 - - Stock Option (Right to Buy)
Lindsey Rolfe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Feb 2025 127,500 255,000 - - Stock Option (Right to Buy)
Michael Byrnes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Feb 2025 127,500 255,000 - - Stock Option (Right to Buy)
Shami J. Patel Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Feb 2025 127,500 255,000 - - Stock Option (Right to Buy)
Kathleen D. Laporte Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Feb 2025 127,500 255,000 - - Stock Option (Right to Buy)
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Feb 2025 254,000 508,000 - - Stock Option (Right to Buy)
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Feb 2025 204,080 204,080 - - Warrant to Purchase Shares of Common Stock
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Feb 2025 306,120 306,120 - - Pre-Funded Warrant
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Feb 2025 204,080 204,080 - - Pre-Funded Warrant
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Feb 2025 306,120 306,120 - - Warrant to Purchase Shares of Common Stock
Lindsey Rolfe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Dec 2024 127,500 127,500 - - Stock Option (Right to Buy)
Michael Byrnes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Dec 2024 127,500 127,500 - - Stock Option (Right to Buy)
Shami J. Patel Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Dec 2024 127,500 127,500 - - Stock Option (Right to Buy)
Kathleen D. Laporte Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Dec 2024 127,500 127,500 - - Stock Option (Right to Buy)
Brian G. Atwood Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Dec 2024 254,000 254,000 - - Stock Option (Right to Buy)
Andrew Albert Kucharchuk Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2024 500,000 500,000 - - Stock Option (Right to Buy)
Kristen Pierce Chief Development Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2024 200,000 200,000 - - Stock Option (Right to Buy)
Kathleen D. Laporte Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Sep 2024 50 0 - - Series A Convertible Preferred Stock
Brian G. Atwood Director Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Sep 2024 1,317,956 0 - - Stock Option (Right to Buy)
Brian G. Atwood Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Sep 2024 19,358,578 19,607,313 - - Common Stock
Brian G. Atwood Director Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Sep 2024 13,857 0 - - Stock Option (Right to Buy)
Brian G. Atwood Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Sep 2024 1,002 0 - - Series A Convertible Preferred Stock
Kathleen D. Laporte Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Sep 2024 965,997 965,997 - - Common Stock
Robyn Rapaport Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 112,500 112,500 - - Stock Option (Right to Buy)
Brian G. Atwood Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 1,317,956 1,317,956 - - Stock Option (Right to Buy)
Daniel Corey Director, Chief Technical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 856,671 856,671 - - Stock Option (Right to Buy)
Lindsey Rolfe Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 112,500 112,500 - - Stock Option (Right to Buy)
Michael Byrnes Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 112,500 112,500 - - Stock Option (Right to Buy)
Kathleen D. Laporte Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Mar 2024 112,500 112,500 - - Stock Option (Right to Buy)
Brian G. Atwood Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2024 1,002 1,002 - - Series A Convertible Preferred Stock
Brian G. Atwood Director, Chief Executive Officer Other type of transaction at price $ 0.00 per share. 14 Feb 2024 148,208 248,735 - - Common Stock
Brian G. Atwood Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2024 1,002 1,002 - - Series A Convertible Preferred Stock
Kathleen D. Laporte Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2024 50 50 - - Series A Convertible Preferred Stock
Brian G. Atwood Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2024 13,857 13,857 - - Stock Option (Right to Buy)
Brian G. Atwood Director, Chief Executive Officer Other type of transaction at price $ 0.00 per share. 14 Feb 2024 100,527 100,527 - - Common Stock
Brian G. Atwood Director, Chief Executive Officer Other type of transaction at price $ 0.00 per share. 14 Feb 2024 148,208 248,735 - - Common Stock
Brian G. Atwood Director, Chief Executive Officer Other type of transaction at price $ 0.00 per share. 14 Feb 2024 100,527 100,527 - - Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures